BioCentury
BioCentury
YouTubeLinkedInXRSS
ARTICLE | Distillery Therapeutics

Neddylation inhibition for insulin resistance

By biocentury staff
March 4, 2022 7:54 PM UTC

DISEASE CATEGORY: Endocrine/metabolic disease

INDICATION: Diabetes...

BCIQ Company Profiles

University of Oklahoma

BCIQ Target Profiles

Cullin E3 ubiquitin ligase complex

Insulin receptor substrate 1 (IRS1)

Insulin receptor substrate 2 (IRS2)

BCIQ Company Profiles

University of Oklahoma

BCIQ Target Profiles

Cullin E3 ubiquitin ligase complex

Insulin receptor substrate 1 (IRS1)

Insulin receptor substrate 2 (IRS2)

About BioCentury

Privacy & Legal

Contact

About BioCentury

Company Overview
Management
Editorial & Research
Scientific Advisory Board

Privacy & Legal

User Agreement
Terms of Use
Privacy Policy
Use of Images & Market Data
Reprints & Permissions

Contact

Contact Us
Advertising & Sponsorship
Customer Resource Center
Career Opportunities
Forgot Password
YouTubeLinkedInXRSS
BioCentury
© 2025 BioCentury Inc. All Rights Reserved.
Copyright © 2025 BioCentury Inc. All Rights Reserved.
YouTubeLinkedInXRSS